Spyre Therapeutics (SYRE) Share-based Compensation (2015 - 2026)

Spyre Therapeutics has reported Share-based Compensation for 12 years, with the latest figure at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 44.55% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $41.6 million (up 4.23% YoY), and the FY2025 full-year result was $37.6 million, down 16.1% from the prior year.
• Share-based Compensation for Q1 2026 stood at $12.8 million, up from $9.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $17.3 million in Q4 2023, with the low at $1.4 million in Q4 2022.
• Historically, Share-based Compensation has averaged $7.9 million across 5 years, with a median of $9.0 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation jumped 1110.23% — and 2024, when it sank 46.64%.
• Spyre Therapeutics' Share-based Compensation stood at $1.4 million in 2022, then jumped by 1110.23% to $17.3 million in 2023, then tumbled by 46.64% to $9.2 million in 2024, then climbed by 6.46% to $9.8 million in 2025, then soared by 30.53% to $12.8 million in 2026.
• The last three Share-based Compensation figures came in at $12.8 million (Q1 2026), $9.8 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.